Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

News Market Reaction – CNTA

The recorded move for CNTA in the trading session of this news was +0.49%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

01/22/2024 - 08:00 AM EST

BOSTON and LONDON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:

Event: Guggenheim’s 6^th Annual Biotechnology Conference
Date: February 7, 2024
Location: NY, NY
Fireside Chat: 9:00 AM ET

Event: Leerink Partners Global Biopharma Conference 2024
Date: March 11, 2024
Location: Miami, FL
Fireside Chat: 10:00 AM ET

Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations.

About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications in rare diseases and immuno-oncology. We operate with the conviction that each one of our programs has the potential to change the current treatment paradigm and establish a new standard of care. For more information, visit www.centessa.com, which does not form part of this release.

Contact:
Kristen K. Sheppard, Esq.
SVP of Investor Relations
investors@centessa.com